Grant: CIHR Fellowship
Direct Payment
$120,000.00
Validation of the innovative clinical endpoint capture methods in the pragmatic multi-center randomized trial "Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long- term Effectiveness (ADAPTABLE)"
EF 2017-18
Résumé
Clinical trials of good quality are necessary to assess the efficacy and safety of new medical treatments. However, long-term follow-up of patients treated with novel therapies is often complex and expensive, hindering the implementation of high-scale research initiatives. To optimize research efficiency, decrease its costs in the perspective of judicious allocation of resources, and, more importantly, to make patients benefit earlier from potential new treatments, innovative research methods are necessary to obtain follow-up. The so-called "registry-based randomized trials" have the potential to simplify follow-up by using pre-existing registries embedded in clinical care, without unnecessary medical outpatient visits.
The purpose of the study is to evaluate the validity of the data obtained through this innovative method, compared to the more costly traditional methods. For this purpose, data from the ADAPTABLE trial will be analyzed. The primary objective of this trial is to identify the best dose of aspirin for prevention of severe cardiovascular events. For this purpose, 20,000 patients will be followed-up for up to 30 months, and data will be collected through electronic health records, without unwarranted medical visits for the patients. This is the largest study of this type ever performed in North America. In a sample of these patients, the traditional method of follow-up (through direct medical contact with the patients) will be performed, and compared to the innovative and less costly method (through pre-existing electronic registries), to assess the validity of the latter method. If it provides follow-up data of good quality, as we expect, this will be an incentive for the development of platforms for registry-based trials adapted to the specific Canadian reality. The ultimate goals are to improve patient care, and to alleviate clinical researchers in all fields of medicine from a significant logistic and administrative burden.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
North Carolina, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
376317
Name
Marquis-Gravel Guillaume
Region
North Carolina
Country
United States of America
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Health Research Training B - HP
Projecttitle
Validation of the innovative clinical endpoint capture methods in the pragmatic multi-center randomized trial "Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long- term Effectiveness (ADAPTABLE)"
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aspirin; Atherosclerotic Cardiovascular Diseases; Cardiology; Patient-Oriented Outcomes; Pragmatic Trial; Randomized Controlled Trial; Secondary Prevention
Abstract
Clinical trials of good quality are necessary to assess the efficacy and safety of new medical treatments. However, long-term follow-up of patients treated with novel therapies is often complex and expensive, hindering the implementation of high-scale research initiatives. To optimize research efficiency, decrease its costs in the perspective of judicious allocation of resources, and, more importantly, to make patients benefit earlier from potential new treatments, innovative research methods are necessary to obtain follow-up. The so-called "registry-based randomized trials" have the potential to simplify follow-up by using pre-existing registries embedded in clinical care, without unnecessary medical outpatient visits.
The purpose of the study is to evaluate the validity of the data obtained through this innovative method, compared to the more costly traditional methods. For this purpose, data from the ADAPTABLE trial will be analyzed. The primary objective of this trial is to identify the best dose of aspirin for prevention of severe cardiovascular events. For this purpose, 20,000 patients will be followed-up for up to 30 months, and data will be collected through electronic health records, without unwarranted medical visits for the patients. This is the largest study of this type ever performed in North America. In a sample of these patients, the traditional method of follow-up (through direct medical contact with the patients) will be performed, and compared to the innovative and less costly method (through pre-existing electronic registries), to assess the validity of the latter method. If it provides follow-up data of good quality, as we expect, this will be an incentive for the development of platforms for registry-based trials adapted to the specific Canadian reality. The ultimate goals are to improve patient care, and to alleviate clinical researchers in all fields of medicine from a significant logistic and administrative burden.
Competitiondate
201711
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Marquis-Gravel, Guillaume
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~